Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids

Ibrahim, Iddrisu; Syamala, Soumyakrishnan; Ayariga, Joseph A.; Xu, Junhuan; Robertson, Boakai K.; Meenakshisundaram, Sreepriya; Ajayi, Olufemi S.

doi:10.3390/metabo12121247

Cited by 27 publications

(22 citation statements)

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The brainstem has a higher quantity of the peptide hormone GLP-1 than other parts of the CNS. Its physiological impacts include glucose metabolism, brain function, and neurological protection (Ibrahim et al, 2022). Several organs, such as the kidney, lung, heart, and CNS, have been shown to have GLP-1 receptors.…”

Section: Alzheimer's Disease (Ad)mentioning

confidence: 99%

Probiotics: Bridging the interplay of a healthy gut and psychoneurological well‐being

Meher,

Acharya,

Sahu

2024

Food Bioengineering

View full text Add to dashboard Cite

The establishment of a healthy microbiota, particularly during infancy, profoundly influences psychological health and neurological function through the gut‐brain axis. This review delves into the intricate connections between probiotics, gut microbiome development, and their impact on neurological disorders. Biotics, live microorganisms with proven health benefits, have emerged as a promising intervention, particularly during critical developmental stages. Administering specific probiotic strains (Lactobacillus species and Bifidobacterium) in infancy has shown promise in preventing and alleviating gut disorders, with implications for psychological well‐being. The bidirectional communication along the gut‐brain axis underscores the potential of probiotics in influencing neurological outcomes, ranging from anxiety to neurodevelopmental disorders. Additionally, this review explores emerging food engineering techniques (microencapsulation, genome editing, fermentation, protein engineering, immobilization, etc.) employed in preparing probiotic‐based foods, ensuring the viability and targeted release of probiotics in the gastrointestinal tract.

show abstract

Section: Alzheimer's Disease (Ad)mentioning

confidence: 99%

Probiotics: Bridging the interplay of a healthy gut and psychoneurological well‐being

Meher,

Acharya,

Sahu

2024

Food Bioengineering

View full text Add to dashboard Cite

show abstract

“…212 Other microbial metabolites, including amino acidderived metabolites, may also cross the placenta, with potential effects on fetal development. 213,214 Further, there is growing evidence for a wide variety of other metabolites, produced through the action of microbiota on dietary nutrients, which may affect host health, including amino acids, 215 soy-derived isoflavones, [216][217][218][219] cannabinoids, 220 and phenolic acids, 221 in addition to a large number of pharmacological and host metabolites that may be modulated by microbiota. 110,[222][223][224][225]…”

Section: Microbial Metabolismmentioning

confidence: 99%

Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease

Gabriel

Ferguson

2023

Circulation Research

View full text Add to dashboard Cite

Cardiometabolic disease comprises cardiovascular and metabolic dysfunction and underlies the leading causes of morbidity and mortality, both within the United States and worldwide. Commensal microbiota are implicated in the development of cardiometabolic disease. Evidence suggests that the microbiome is relatively variable during infancy and early childhood, becoming more fixed in later childhood and adulthood. Effects of microbiota, both during early development, and in later life, may induce changes in host metabolism that modulate risk mechanisms and predispose toward the development of cardiometabolic disease. In this review, we summarize the factors that influence gut microbiome composition and function during early life and explore how changes in microbiota and microbial metabolism influence host metabolism and cardiometabolic risk throughout life. We highlight limitations in current methodology and approaches and outline state-of-the-art advances, which are improving research and building toward refined diagnosis and treatment options in microbiome-targeted therapies.

show abstract

“…Synergistic studies of polymyxin B and CBD co-therapy demonstrated strong antibacterial activities against Acinetobacter baumannii ATCC 19606 and other gram-negative bacteria ( Klebsiella pneumoniae and Pseudomonas aeruginosa ) ( 9 ). Some non-pathogenic bacteria such as gut microbiota is an integral aspect of human health, and while food and antibiotic consumption does affects the gut microbiota and sometimes provides an easy pathway for infections arising from foodborne pathogens ( 10 ), CBD has been demonstrated to boost enzyme activities of these gut bacteria ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

CBD resistant Salmonella strains are susceptible to epsilon 34 phage tailspike protein

Ibrahim

Ayariga

et al. 2023

Front. Med.

Self Cite

View full text Add to dashboard Cite

The rise of antimicrobial resistance is a global public health crisis that threatens the effective control and prevention of infections. Due to the emergence of pandrug-resistant bacteria, most antibiotics have lost their efficacy. Bacteriophages or their components are known to target bacterial cell walls, cell membranes, and lipopolysaccharides (LPS) and hydrolyze them. Bacteriophages being the natural predators of pathogenic bacteria, are inevitably categorized as “human friends”, thus fulfilling the adage that “the enemy of my enemy is my friend”. Leveraging on their lethal capabilities against pathogenic bacteria, researchers are searching for more ways to overcome the current antibiotic resistance challenge. In this study, we expressed and purified epsilon 34 phage tailspike protein (E34 TSP) from the E34 TSP gene, then assessed the ability of this bacteriophage protein in the killing of two CBD-resistant strains of Salmonella spp. We also assessed the ability of the tailspike protein to cause bacteria membrane disruption, and dehydrogenase depletion. We observed that the combined treatment of CBD-resistant strains of Salmonella with CBD and E34 TSP showed poor killing ability whereas the monotreatment with E34 TSP showed considerably higher killing efficiency. This study demonstrates that the inhibition of the bacteria by E34 TSP was due in part to membrane disruption, and dehydrogenase inactivation by the protein. The results of this work provides an interesting background to highlight the crucial role phage protein such as E34 TSP could play in pathogenic bacterial control.

show abstract

Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids

Cited by 27 publications

References 241 publications

Probiotics: Bridging the interplay of a healthy gut and psychoneurological well‐being

Probiotics: Bridging the interplay of a healthy gut and psychoneurological well‐being

Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease

CBD resistant Salmonella strains are susceptible to epsilon 34 phage tailspike protein

Contact Info

Product

Resources

About